- Home
- / Homology Medicines
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Homology Medicines financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$53.7 M
FY, 2025
CreditSafe Score
?
Score changed on Jul 20, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7M | 1.7M | 2.7M | 34.0M | 3.2M | 1.2M | 53.7M | |||
| General and administrative expense | 4.3M | 8.3M | 17.3M | 22.2M | 32.6M | 36.8M | 38.1M | 31.3M | 18.0M | 17.7M |
| Operating expense total | 10.0M | 29.7M | 65.2M | 111.6M | 133.0M | 136.5M | 67.6M | 36.8M | ||
| EBIT | (10.0M) | (29.7M) | (61.6M) | (109.9M) | (130.3M) | (95.9M) | (101.4M) | (66.1M) | 16.9M | |
| EBIT margin, % | -1671.1% | -6599.2% | -4821.0% | 31.5% | ||||||
| Investment income | 4.3M | 6.0M | 1.6M | 185.0K | 3.2M | 5.6M | (1.6M) | |||
| Interest income | 24.2K | 542.6K | ||||||||
| Interest expense | 2.8M | |||||||||
| Pre tax profit | 1.2M | (87.1M) | (46.1M) | 29.8M | ||||||
| Income tax expense | 715.0K | 21.0K | ||||||||
| Net Income | (8.0M) | (30.0M) | (57.2M) | (103.9M) | (128.7M) | (95.8M) | (5.0M) | (113.0M) | (47.7M) | 29.8M |
| EPS | (4.2) | (12.1) | (0.1) | (1.0) | (6.6) | 2.4 |